Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Blood

Volumn 118, Issue 23, 2011, Pages 5989-5995

  Zamagni, Elena ^a   Patriarca, Francesca ^b   Nanni, Cristina ^a   Zannetti, Beatrice ^a   Englaro, Emanuela ^c   Pezzi, Annalisa ^a   Tacchetti, Paola ^a   Buttignol, Silvia ^b   Perrone, Giulia ^a   Brioli, Annamaria ^a   Pantani, Lucia ^a   Terragna, Carolina ^a   Carobolante, Francesca ^b   Baccarani, Michele ^a   Fanin, Renato ^b   Fanti, Stefano ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 82955189267     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361386     Document Type: Article

References (24)

1. Kumar SK, Rajkumar V, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
2. Stewart AK, Richardson PJ, San Miguel FJ. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-5443.
3. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376(9758):2075-2085.
4. Cavo M, Rajkumar VS, Palumbo A. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous-stem cell transplantation. Blood. 2011;117(23):6063- 6073.
5. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008;113(2):355-359.
6. Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
7. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implication. J Clin Oncol. 2007;25(9):1121-1128. (Pubitemid 46596765)
8. Nanni C, Zamagni E, Farsad M, et al. Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525-531.
9. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging of the spine and pelvis and whole-body planar radiographs in the imaging assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-55. (Pubitemid 46232657)
10. Bredella MA, Steinbach L, CaputoG, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Radiol. 2005;184(4):1199-1204. (Pubitemid 43821897)
11. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after two cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337-1343.
12. Terasawa T, Dahabreh IJ, Nihashi T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist. 2010;15(7):750-759.
13. Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-2076.
14. Cavo M, Di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol. 2009;27(30):5001-5007.
15. Bladè J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
16. Greipp P, San Miguel J, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;15(1):1-9.
17. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myeaposlome. Blood. 2007;109(8):3489-3495. (Pubitemid 46572539)
18. Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009;27(25):4197-4203.
19. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36(3):842-854.
20. Dimopoulos M, Kyle R, Fermand JP, et al. Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701-4705.
21. Durie GM,WaxmanAD, D'Agnolo A, Williams CM. Whole body 18F-FDG-PET identifies high-risk myeloma. J Nucl Med. 2002;43(11):1457-1463.
22. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59. (Pubitemid 43053523)
23. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
24. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)